Targets › CYSLTR1
10 programs from 10 companies in 10 trials: 4 Phase 2, 2 Phase 3, 2 Phase 4, 2 Phase 1; Other, Cardiovascular, Immunology; next expected readout Dec 2026.
Receptor for cysteinyl leukotrienes mediating bronchoconstriction of individuals with and without asthma. Stimulation by LTD4 results in the contraction and proliferation of smooth muscle, edema, eosinophil migration and damage to the mucus layer in the lung. (UniProt, Q9Y271)
Open in Phaseline: the race on CYSLTR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Colorado, Denver | Montelukast Cysteinyl leukotriene receptor 1 antagonist | CYSLTR1 | Phase 4 | Albuminuria | Feb 2027 |
| House Ear Institute | Montelukast Cysteinyl leukotriene receptor 1 antagonist | CYSLTR1 | Phase 4 | Meniere Disease | – |
| Shanghai Zhongshan Hospital | Montelukast Cysteinyl leukotriene receptor 1 antagonist | CYSLTR1 | Phase 3 | Myocardial Infarction (MI) | Feb 2027 |
| Sherief Abd-Elsalam | Montelukast Cysteinyl leukotriene receptor 1 antagonist | CYSLTR1 | Phase 3 | Rheumatoid Arthritis | Oct 2027 |
| MediciNova | MN-001 (tipelukast) Cysteinyl leukotriene receptor antagonist | CYSLTR1 | Phase 2 | Diabetes Mellitus, Type 2 | Dec 2026 |
| Phramongkutklao College of Medicine and Hospital | Montelukast Cysteinyl leukotriene receptor 1 antagonist | CYSLTR1 | Phase 2 | Dengue | Jan 2027 |
| October 6 University | Montelukast Cysteinyl leukotriene receptor 1 antagonist | CYSLTR1 | Phase 2 | Acute Myocardial Infarction (AMI) | May 2027 |
| Pakistan Institute of Medical Sciences | Montelukast Cysteinyl leukotriene receptor 1 antagonist | CYSLTR1 | Phase 2 | Acute Bronchiolitis | – |
| Duke University | montelukast Cysteinyl leukotriene receptor 1 antagonist | CYSLTR1 | Phase 1 | Bronchopulmonary Dysplasia (BPD) | Jun 2027 |
| Baylor College of Medicine | Montelukast Cysteinyl leukotriene receptor 1 antagonist | CYSLTR1 | Phase 1 | Gulf War Syndrome | Apr 2028 |
Dengue (1) Myocardial Infarction (MI) (1) Diabetes Mellitus, Type 2 (1) Acute Myocardial Infarction (AMI) (1) Albuminuria (1) Acute Bronchiolitis (1) Meniere Disease (1) Rheumatoid Arthritis (1) Gulf War Syndrome (1) Bronchopulmonary Dysplasia (BPD) (1)
small molecule (10)
Phramongkutklao College of Medicine and Hospital (1) Shanghai Zhongshan Hospital (1) MediciNova (1) October 6 University (1) University of Colorado, Denver (1) Pakistan Institute of Medical Sciences (1) House Ear Institute (1) Sherief Abd-Elsalam (1) Baylor College of Medicine (1) Duke University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.